This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiationfree, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninetytwo untreated FL patients aged p60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68 months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected longterm progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximabsupplemented conventional chemotherapy.
Introduction
Follicular lymphoma (FL) is the second most frequent lymphoma subtype in developed countries. 1 Median survival time is 8-10 years, but life expectancy is shorter in patients with poor prognostic factors. [2] [3] [4] [5] FL is considered incurable despite its high chemosensitivity, as relapses always occur, following progressively shorter remission phases. The recent introduction of effective new drugs, namely naked and radiolabeled anti-CD20 monoclonal antibodies, has improved treatment of FL. [6] [7] [8] [9] [10] [11] Unfortunately, recurrence is still frequent, particularly in patients with advanced disease and unfavorable prognostic presentation, and the vast majority of patients die from their disease.
Owing to the high risk of disease recurrence, chemotherapeutic intensification with autologous stem cell transplantation (ASCT) has been explored in FL, with conflicting results. When used at disease relapse, ASCT improved overall survival (OS) versus standard salvage approaches, and some patients achieved durable molecular remission. [12] [13] [14] [15] [16] [17] When employed as first-line therapy, ASCT was the only treatment offering prolonged clinical remission in patients with high risk disease in the premonoclonal antibody age. Moreover, extensive and prolonged molecular follow-up suggested the possibility of cure at least in a subgroup of patients. [18] [19] [20] [21] [22] [23] On the other hand, treatment tolerability has been a major concern in this setting. The risk of early toxicity has limited the inclusion of ASCT in multicenter trials. Late toxicities (particularly secondary myelodysplasia and acute myeloid leukemia (sMDS/AML)) have negatively impacted the long-term outcome of patients treated with ASCT [24] [25] [26] leading to comparable OS curves despite an improved control of primary disease. 27, 28 These observations have discouraged the widespread use of ASCT as front-line therapy for FL.
In 2002, we published the short-term results of a prospective trial employing intensified high-dose sequential (i-HDS) chemotherapy and ASCT in 92 FL patients at diagnosis treated between 1996 and 1999, 18 and showed that the results obtained with ASCT in single center studies in highly qualified institutions could be reproduced in the context of a multicenter trial. The report is now updated at 40 months from the previous closing date. Median follow-up is now 68 months (range 5-101) and the study is mature for long-term outcome evaluation. The aim of the study was to assess in this cohort of patients prospectively managed upfront with i-HDS and ASCT (i) the long-term survival, (ii) the chances of prolonged survival in the absence of clinical and molecular disease and (iii) the risk of developing secondary malignancies.
Patients and methods

Patient characteristics
Between December 1996 and February 1999, at 20 Italian Hematology or Oncology Units affiliated to the Gruppo Italiano Trapianto Midollo Osseo (GITMO), 92 patients were treated with the i-HDS program as front-line therapy. The planned enrolment was 96 patients in 3 years. The sample size was calculated considering the accrual potential of participating Centers (median number of ASCT/year: 31; range: 8-96) 18 and the small proportion of FL patients who were usually referred to specialized Hematology Units in the late 1990s in Italy. Thus considering the strict eligibility criteria detailed below, and the presence of severe delays in Institutional Review Board approval in 30% of centers, the number of patients included was very close to what could be expected for this patient population.
Eligibility criteria for the study protocol have been reported. 18 Briefly, patients aged 18-60 with a histological diagnosis of stage III-IV FL at the International Working Formulation (WF B, C or D) 29 or Revised European and American Lymphoma classification (REAL grade I, II or III) 30 were considered eligible if presenting with at least one of the following adverse prognostic features: bulky disease (45 cm), high serum lactic dehydrogenase (LDH), disease-related compression symptoms, systemic 'B' symptoms, Eastern Cooperative Oncology Group performance status X2 or bone marrow (BM) invasion more than 20%. In addition, patients had to be chemotherapy-naive and free of concurrent heart, kidney, lung or liver disease including hepatitis B and C. Patients with HIV-positivity CNS disease or histological transformations were also excluded from the trial. Informed consent was obtained for every patient and the Institutional Review Boards of all participating centers approved the study. Eighty-four percent had Ann Arbor stage IV disease. BM involvement was present in 80%, whereas extranodal sites of disease other than the BM were present in 55%. Fifty-one percent had a bulky mass and 37% had an elevated serum LDH concentration. 'B' symptoms were present in 30% and leukemic disease (peripheral blood lymphocytes 412 000/mm 3 ) in 12% patients. Age-adjusted International Prognostic Index (aaIPI) score was 2 or above in 37% patients. Owing to lack of information on the number of involved sites and ESR, we were not able to retrospectively classify our patients by the IIL and FLIPI score. 31, 32 Unfortunately, it was also impossible to retrospectively reclassify patients according to histological grade.
Treatment schedule
The i-HDS regimen has already been described 18, 21 ( Figure 1 ). Briefly, it consists of intensive debulking before the high-dose phase, including two complete, full-dose APO (doxorubicin, vincristine, prednisone) courses, totaling four 75 mg/m 2 doxorubicin administrations 33 (although the first dose could be reduced to 50 mg/m 2 ). Patients not achieving CR following these courses received two DHAP (Ara-C, cisplatin, dexamethasone) courses. The high-dose phase consisted of etoposide (VP16) 2 g/m 2 followed by methotrexate (MTX) 8 g/m 2 and cyclophosphamide (CTX) 7 g/m 2 . Peripheral blood progenitor cell (PBPC) collection was scheduled after the last course to exploit the 'in vivo purging effect' operated by high-dose chemotherapy. A chemotherapy-free interval of 40 days was scheduled before high dose CTX 7 g/m 2 , to allow optimal PBPC mobilization. Three hd dexamethasone courses (dexamethasone at 40 mg/day for 4 consecutive days) were administered every 10 days during this interval. A minimum of 5 Â 10 6 CD34 þ cells/kg were required for autologous transplantation with PBPCs alone. Patients failing to achieve this minimum were taken off therapy. The conditioning regimen for autologous transplantation consisted of mitoxantrone (MITO) 60 mg/m 2 on day À5 and melphalan (L-PAM) 180 mg/m 2 on day À2. 34 PBPCs were reinfused on day 0. Granulocyte colony-stimulating factor was given at 5 mg/kg daily following VP16, CTX and autograft. Radiotherapy was scheduled on bulky sites or on residual masses approximately 2 months after autograft. As mentioned, Rituximab was not yet available at the time the protocol was performed and therefore the schedule did not include this drug.
Evaluation and statistics
Clinical response was assessed by complete restaging including CT scans and BM biopsy at 2 months after autograft, thereafter at 3-month intervals for the first year and then 6 monthly. Response was assessed following Cheson criteria. 35 All patients started on treatment were considered evaluable for response and outcome was assessed on an intention-to-treat basis. OS was measured from the start of therapy to the date of death or last follow-up. 35 Progression-free survival (PFS) for all patients was taken from the start of therapy until disease progression or death from lymphoma. 35 Disease-free survival (DFS) for patients in CR was measured from the first recording of CR to the date of progression. 35 Event-free survival (EFS) was calculated from the start of therapy to the first adverse event, that is relapse or progression, death for any cause or last follow-up alive. 35 The last outcome evaluation to whom all Centers were able to provide patient information was 1 June 2004 (30 months after the closing date of the previous report). An additional outcome evaluation was requested in 2005 with closing date fixed at 30 April (40 months from the closing date of the previous report). Fifteen centers accounting for 77% of overall enrolment complied with this request. OS, DFS, PFS and EFS were calculated by the Kaplan-Meyer method. 36 The log-rank test was used to compare survival curves. 37 Cumulative incidence functions were estimated by the Cox regression model for competing risks. 38 MDS definition required peripheral cytopenia and BM dysplasia in at least two lineages or presence of cytogenetic abnormalities associated with MDS and acute myeloid leukemia.
Minimal residual disease assessment by nested PCR
Nested PCR amplification for both the major breakpoint region and the minor cluster region of the bcl-2/IgH rearrangement was carried out as originally described by Gribben et al. 16, 39 In Bcl-2/IgH-negative patients, an alternative tumor marker was sought by amplifying and sequencing the immunoglobulin heavy-chain rearrangement. 40 PCR detection of minimal residual disease (MRD) was then performed as described elsewhere. 16, 39, 40 PCR analysis was performed at diagnosis on PBPC and BM samples obtained before autologous transplantation, and then at 6-month intervals following autologous transplantation for 2 years. Patients were considered as having PCR-negative harvests if at least one PBPC or BM harvest was PCR-negative. Molecular remission was defined as absence of molecular disease in two consecutive BM samples (spaced by at least 6 months) in a patient showing standard radiologic and histologic evidence of CR.
Results
Treatment feasibility and early toxicity
Treatment feasibility and short-term outcome have been reported elsewhere. 18 Briefly, the i-HDS schedule proved to be feasible at the multicenter level with 80 patients (87%) completing the program. Treatment-related toxic events included two toxic deaths and 12 grade III-IV extra-hematological non-fatal toxicities (other than oral and gastrointestinal mucositis during the myeloablative phase). During the first year from transplantation, the following toxicities were recorded: (i) herpes zoster reactivation in three patients; (ii) congestive heart failure in three patients, in all cases responsive to medical treatment (New York Heart Association (NYHA) I in two patients and NYHA II in one patient); (iii) autoimmune thrombocytopenia that resolved spontaneously and (iv) autoimmune hemolytic anemia successfully treated with splenectomy.
Long-term clinical outcome. Figure 2 shows the survival projections. At a median follow-up of 68 months, 74 of 92 (80%) patients are alive with an estimated 5.5-year OS projection of 80% (Figure 2a) . The most frequent causes of death were treatment-related death (two patients), progressive FL (13 patients), sMDS/AML (one patient) solid cancer (one patient) and T-cell acute lymphoblastic leukemia (one patient). At present, 46 (50%) patients are alive and in continuous CR at a median follow-up of 73 months (range 5-100 months). At a median follow-up of 48 months, the 4-year PFS, EFS and DFS projections are 62, 60 and 65%, respectively (Figure 2b-d) . The long-term outcome was also evaluated by aaIPI score: patients with score 0-1 (low risk) had a comparable OS and PFS to patients with score X2 (intermediate-high risk) (Figure 3a and b). As aaIPI did not correlate with outcome, we tried to verify if additional clinical parameters were prognostically relevant. We considered age (4 or o median value of the series), sex, Hb value (4 or o 12 g/dl), Ann Arbor stage IV, X2 extranodal disease sites, bulky disease and BM involvement. None of them appeared to be associated with outcome, with the exception of BM involvement and bulky disease (Po0.05). Stage IV approached but did not reach statistical significance.
Overall, 32 patients in CR relapsed at a median time from ABMT of 18 months (range 3-68 months). With a median of 24 months' observation from relapse, 21 relapsed patients are still alive (median OS not reached) (Figure 4 ). Second-line salvage therapy included rituximab in 72% of patients. Patients not receiving rituximab were treated with radiotherapy (two patients), fludarabine-free salvage therapy (two patients), fludarabine-containing therapy (two patients) and allogeneic transplantation (three patients). Patients treated with rituximab at relapse received the following regimens: rituximab7radiother-apy (four patients), rituximab-supplemented fludarabine-free salvage therapy such as R-CHOP (four patients) and rituximab þ fludarabine-containing therapy (15 patients). Moreover, 17 of 32 patients at relapse achieved a second CR, 15 through a rituximab-containing regimen and two through radiotherapy alone.
Correlation of long-term outcome with PCR analysis.
As described previously, a molecular marker was obtained from the diagnostic tissue in 42 of 55 patients tested molecularly (76%). The tumor marker was the Bcl-2/IgH translocation in 36 patients and the IgH sequence in six patients. The prognostic value of PCR status of stem cell harvests and that of molecular remission achievement were assessed. Both were highly significant for the long-term outcome of this patient series. Of the 20 patients obtaining one or more PCR-negative harvests, 17 (85%) maintained CR. In contrast, 13 of the 22 patients (59%) collecting only PCR-positive harvests relapsed (Po0.01). PFS curves of the two populations are shown in Figure 5a . Of the 24 patients obtaining molecular remission, 20 are still in complete remission. In contrast, 10 relapses occurred in the 13 patients who failed to achieve post-autograft molecular remission (Po0.001). PFS curves of patients achieving post-graft molecular remission compared to those remaining PCR-positive are shown in Figure 5b (Po0.001).
Long-term clinical follow-up: late toxicity and second malignancies
No new grade III-IV non-neoplastic events occurred 1 year or more after transplantation except for one patient who had deep venous thrombosis and was later found positive for factor V Leiden mutation. The three patients with congestive heart failure showed no clinical sign of deterioration in terms of NYHA grade and treatment requirements. Functional studies were also stable or slightly improved.
With a median follow-up of 62 months from the end of treatment, the 5-year cumulative risk of developing sMDS/AML was 3.7% ( Figure 6 ). Median time between transplant and MDS development was 32 months (range 24-78). The 5-year cumulative risk of developing a solid tumor is 1.3% ( Figure 6 ). In addition, one case of acute T-cell lymphoblastic leukemia was recorded. Of the five cases of sMDS/AML, one occurred in a patient who had not undergone additional chemotherapy following ABMT (he had a local relapse treated with radiotherapy); this patient was treated with observation for 10 months after which, following hematopoietic deterioration, he underwent allogeneic transplantation (allo-BMT). He is presently in CR for both MDS and FL at 41 months from allogeneic-BMT. Four patients developed sMDS/AML following repeated courses of salvage chemotherapy, radiotherapy and immunotherapy owing to relapsed or resistant FL. One patient received Rituximab, chlorambucil and radiotherapy as salvage therapy. The remaining three received 4-6 courses of Rituximabsupplemented Fludarabinee-containining regimens. Two of them have died of AML and progressive FL, respectively. The other two patients are still alive with stable hematopoietic function; one refused allogeneic transplantation despite the availability of an HLA-identical donor. We report one fatal lung cancer developing at 42 months after ABMT in a heavy smoker and one pancreatic carcinoma developing at 68 months from ABMT. This second patient is still alive in supportive therapy.
Discussion
The long-term outcome of the GITMO consecutive trial, which enrolled 92 FL at diagnosis between 1997 and 1999, is reported. All patients had advanced disease and were treated with i-HDS, a TBI-free intensified high-dose chemotherapy program with PBSC transplantation. No Rituximab supplementation was planned. The prolonged follow-up shows that 50% of patients remain long-term progression-free survivors following i-HDS. In addition, most of the relapsing patients were successfully rescued with salvage treatments. These features combined to produce a prolonged survival, with a 5.5-year OS projection of 80%. Molecular monitoring on stem cell harvests and in the first 2 years following transplantation retains high predictive value also for the late clinical history, with a PFS projection of 81% at 5.5 years for patients collecting PCR-negative harvests or achieving molecular remission in the early post-transplant phases. Finally, the incidence of secondary neoplasms was lower than observed with alternative intensified treatments, with an actuarial 5-year risk of developing sMDS/AML of 3.7%.
The i-HDS regimen was originally developed in Torino and represents an effort to adapt to indolent lymphomas the HDS schedule designed for diffuse large cell lymphoma by Gianni et al. 41 As the original HDS, it is characterized by high-dose delivery of single agents before a final autografting phase. The main differences are a debulking with conventional chemotherapy before the high-dose schedule and a delayed stem cell collection placed immediatiately before the myeloablative phase to induce a chemotherapy-based in vivo purging of stem cell harvests. Several aspects characterize i-HDS: the intensified pre-autografting phase, the TBI-free nature of the conditioning regimen and the use for autografting of large amounts of PBSC harvested following a sort of in vivo purging operated by chemotherapy. 18, 21 These aspects may explain the acceptable toxicity and the high-response rate observed in this multicenter trial, in spite of the absence of additional Rituximab, not yet available at the time the study was carried out. Indeed, as stated in our previous report, 81 patients (88%) achieved CR. The prolonged follow-up indicates that the response was durable, with a 4-year DFS projection of 65%. Nevertheless, relapse represented the major cause of treatment failure, with 32 (39%) of 81 CR patients showing disease recurrence.
Relapse following autologous transplantation is often seen as an end-stage condition, as chances of a novel response are expected to be low, whereas toxicity is expected to be high. Our trial did not include a common salvage regimen and patients underwent different treatments, at their treating physician's discretion. Our first observation is that relapse was frequently limited and the disease not particularly aggressive. This enabled several patients to be managed with conservative approaches such as radiotherapy or Rituximab alone. Even for more severe relapses, the outcome was not different from what can be expected in patients relapsing after a conventional regimen. Indeed our patients were both fludarabine and rituximab-naive and most had significant benefit from treatments including these agents. Furthermore, autografting with large amounts of PBSC may have ensured adequate hematological compliance to further cytotoxic treatments. These aspects explain why the long-term outcome of relapsing patients was not dismal, and their OS projection quite similar to that reported for patients failing a conventional-dose regimen. 42, 43 Both the durable response and the manageable recurrences are responsible for the prolonged survival; the updated OS projection of 80% at 5.5 years is analogous to that observed in our previous analysis after a shorter (3.5 years) median followup 18 . As reported in the short-term evaluation, we found no outcome difference according to aaIPI. This observation should not be over-emphasized, as aaIPI was assigned retrospectively, whereas more modern scores such as the FLIPI could not be assigned for lack of critical information. In addition, even lowrisk patients presented some adverse factors such as bulky disease or BM involvement, which the aaIPI does not take into account. Indeed, both these features were associated to a poor prognosis in this series. Thus, the low aaIPI patients included in our trial do not represent a typical low-risk population. On the other hand, the updated results confirm that i-HDS is particularly suitable for patients with poor-prognostic features at presentation. This explains why we decided to include only aaIPI X2 patients in the new randomized GITMO trial on FL. Enrollment in this study, which compares i-HDS and CHOP, both supplemented with Rituximab, closed in March 2005, and early results seem to indicate a higher response rate with R-HDS versus R-CHOP in the aaIPI 2-3 subgroup (Ladetto et al., Blood 2005; 106: abstract 675).
MRD evaluation by nested PCR of the t(14;18) is considered to be a major prognostic factor in FL. 16, 17, 23, [44] [45] [46] [47] [48] Our trial basically confirms this finding. However, the use of PCR as a clinical prognostic indicator in FL has some limitations. One of the major problems is the need for repeated and expensive BM assessments throughout the prolonged disease history of these patients. In this trial, we were unable to prolong molecular follow-up for more than 3 years from the end of treatment. However, we observed that achievement of PCR-negativity, in stem cell harvests or in early post-transplant phases, confers a PFS advantage, which persists for many years following the end of treatment. This suggest that a small number of well-chosen time points might allow a feasible and successful MRD monitoring in the vast majority of patients.
The potential risk of inducing secondary malignancies, particularly sMDS/AL, is a major concern. [24] [25] [26] Indeed, an increased incidence of secondary malignancies is well known in indolent lymphoma also following conventional dose chemotherapy. 49 The risk of sMDS/AL seems to rise with the use of novel regimens including fludarabine and/or rituximab. 50, 51 It is commonly accepted that high-dose chemotherapy with autograft may increase the risk of sMDS/AL, although the incidences reported in different studies are variable, with actuarial risk ranging from 3 to 10% and even up to 20% at 10 years. [24] [25] [26] The discrepancy among studies can be explained by differences concerning patient inclusion criteria, source of hemopoietic cells for autograft, induction treatments and conditioning regimens. 52 Indeed, the recently published GOE-LAMS trial has shown that the intensified arm provides a clear advantage in terms of PFS compared to conventional chemotherapy. 27 However, the advantage observed is not reflected in improved OS, chiefly owing to the high incidence of secondary tumors.
In our series, the actuarial risk of sMDS/AL at 5 years was 3.7%, which is similar to the risk observed by Lenz et al. 26 following ABMT. However, the actuarial risk of sMDS/AL following i-HDS is clearly lower than either the crude 6.8% recorded in the GOELAMS trial and the 5-year 10% actuarial risk reported by the Dana Farber group. 24, 53 It is conceivable that the use of a TBI-free conditioning regimen in our i-HDS program reduced both the early and the long-term complications of autograft, including the onset of sMDS/AL. In addition, the rapid and complete hematological recovery following autograft with large quantities of PBSC not exposed to ex vivo purging processes may also have concurred to lower the risk of sMDS/AL. Lastly, the achievement of a durable CR may be crucial in view of the role repeated chemotherapy delivery plays in sMDS/AML development. Indeed, in our series, all but one case of sMDS/AL occurred in patients receiving multiple cytotoxic courses to treat lymphoma recurrence.
Two cases of solid cancers occurred in the series. One was a heavy cigarette smoker both before and after diagnosis of FL. It is difficult to measure the impact of high-dose therapy and autograft on solid tumor development, owing to their high incidence in the general population, and long natural history and the coexistence of multiple risk factors. In their large study, Baker et al. 54 showed that transplanted patients have a 2.8 standardized incidence ratio (SIR) of solid tumors, chiefly due to an increased risk of melanoma, brain and oral cavity cancers. Without wishing to give this undue importance, it undoubtedly represents a weaker association than the SIR of 300 observed with sMDS/AML and will probably have a weaker impact on the overall outcome of autografted patients.
The superiority of intensified versus conventional programs has been over-debated in the FL field. 52 Two recent randomized studies found a significantly higher PFS projection in autografttreated patients versus controls receiving conventional chemotherapy. 26, 27 However, the improved response to treatment did not translate into significantly improved OS, which was attributed at least in the French study to an excess of long-term treatment-related complications. Unfortunately, neither studies included Rituximab -currently, programs devoid of Rituximab can no longer be considered standard controls for FL. Indeed, Rituximab has made obsolete any speculation on the superiority of intensified Rituximab-free regimens versus conventional Rituximab-free regimens. Previous observations have shown that HDS can easily be combined with Rituximab with the additive effect of powerful Rituximab-mediated in vivo purging. 55, 56 Thus, Rituximab-supplemented HDS appears to be an attractive option in studies aiming to verify whether doseintensification is still worthwhile in the monoclonal antibody era. Randomized trials are ongoing and will hopefully provide an answer to this important matter (Ladetto et al., Blood 2005; 106 abstract 675).
